Mirum Pharmaceuticals (MIRM) Research & Development (2019 - 2026)

Mirum Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $97.9 million for Q1 2026.

• On a quarterly basis, Research & Development rose 138.55% year-over-year to $97.9 million in Q1 2026; TTM through Mar 2026 was $238.0 million, a 59.28% increase from a year earlier, with the FY2025 full-year figure at $186.2 million, up 32.39% from the prior year.
• Research & Development rose to $97.9 million in Q1 2026 per MIRM's latest filing, from $51.1 million in the prior quarter.
• Across five years, Research & Development topped out at $97.9 million in Q1 2026 and bottomed at $22.0 million in Q2 2023.
• The 5-year median for Research & Development is $31.7 million (2024), against an average of $37.0 million.
• Across the five-year window, Research & Development plunged 36.83% in 2022 and surged 138.55% in 2026, its largest moves.
• Year by year, Research & Development stood at $31.1 million in 2022, then dropped by 0.55% to $30.9 million in 2023, then soared by 42.32% to $44.0 million in 2024, then grew by 16.08% to $51.1 million in 2025, then soared by 91.58% to $97.9 million in 2026.
• Per Business Quant, the three latest MIRM Research & Development figures stand at $97.9 million (Q1 2026), $51.1 million (Q4 2025), and $43.0 million (Q3 2025).